These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9191528)

  • 1. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix.
    Papadimitriou CA; Dimopoulos MA; Giannakoulis N; Sarris K; Vassilakopoulos G; Akrivos T; Voulgaris Z; Vlahos G; Diakomanolis E; Michalas S
    Cancer; 1997 Jun; 79(12):2391-5. PubMed ID: 9191528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.
    Long HJ; Cross WG; Wieand HS; Webb MJ; Mailliard JA; Kugler JW; Tschetter LK; Kardinal CG; Ebbert LP; Rayson S
    Gynecol Oncol; 1995 May; 57(2):235-9. PubMed ID: 7729741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
    Long HJ; Rayson S; Podratz KC; Abu-Ghazaleh S; Suman V; Hartmann LC; Levitt R; Nair S; Hatfield AK; Knost JA
    Am J Clin Oncol; 2002 Dec; 25(6):547-51. PubMed ID: 12477995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
    Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
    Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
    Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
    Long HJ; Monk BJ; Huang HQ; Grendys EC; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
    Gynecol Oncol; 2006 Mar; 100(3):537-43. PubMed ID: 16216315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
    J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.
    Dowdy SC; Boardman CH; Wilson TO; Podratz KC; Hartmann LC; Long HJ
    Am J Obstet Gynecol; 2002 Jun; 186(6):1167-73. PubMed ID: 12066092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Deliveliotis C; Bafaloukos D; Kalofonos C; Xiros N; Zervas A; Mitropoulos D; Samantas E; Pectasides D; Papakostas P; Gika D; Kourousis C; Koutras A; Papadimitriou C; Bamias C; Kosmidis P; Dimopoulos MA;
    J Clin Oncol; 2004 Jan; 22(2):220-8. PubMed ID: 14665607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
    Logothetis CJ; Dexeus FH; Sella A; Amato RJ; Kilbourn RG; Finn L; Gutterman JU
    J Natl Cancer Inst; 1990 Apr; 82(8):667-72. PubMed ID: 2181151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
    Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.
    Papadimitriou CA; Sarris K; Moulopoulos LA; Fountzilas G; Anagnostopoulos A; Voulgaris Z; Gika D; Giannakoulis N; Diakomanolis E; Dimopoulos MA
    J Clin Oncol; 1999 Mar; 17(3):761-6. PubMed ID: 10071264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
    Ochi T; Ozawa A; Tanji N; Yanagihara Y; Yanagaki T; Miyauchi Y; Ikeda T; Shimamoto K; Toshino A; Sugawara T; Hamada H; Yokoyama M
    Nihon Hinyokika Gakkai Zasshi; 2006 Sep; 97(6):777-81. PubMed ID: 17025209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
    Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
    Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
    Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial.
    Colon-Otero G; Niedringhaus RD; Hillman SH; Geyer S; Sloan J; Krook JE; Windschitl HE; Marks RS; Wiesenfeld M; Tschetter LK; Jett JJ;
    Am J Clin Oncol; 2001 Dec; 24(6):551-5. PubMed ID: 11801752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.